Revenue Breakdown
Composition ()
No data
Revenue Streams
STAAR Surgical Co (STAA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ICLs, accounting for 97.4% of total sales, equivalent to $41.50M. Another important revenue stream is Other surgical products. Understanding this composition is critical for investors evaluating how STAA navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, STAAR Surgical Co maintains a gross margin of 82.21%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 25.80%, while the net margin is 9.38%. These profitability ratios, combined with a Return on Equity (ROE) of -24.65%, provide a clear picture of how effectively STAA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, STAA competes directly with industry leaders such as CDNA and BFLY. With a market capitalization of $947.58M, it holds a significant position in the sector. When comparing efficiency, STAA's gross margin of 82.21% stands against CDNA's 67.24% and BFLY's 55.71%. Such benchmarking helps identify whether STAAR Surgical Co is trading at a premium or discount relative to its financial performance.
